Niagen Bioscience (NASDAQ:NAGE) Downgraded by Wall Street Zen to Hold

Wall Street Zen downgraded shares of Niagen Bioscience (NASDAQ:NAGE) from a buy rating to a hold rating in a research note published on Saturday.

A number of other brokerages also recently commented on NAGE. Canaccord Genuity Group reduced their target price on shares of Niagen Bioscience from $14.00 to $13.00 and set a “buy” rating for the company in a report on Thursday. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Niagen Bioscience in a research report on Thursday, January 22nd. Three equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $16.00.

Niagen Bioscience Trading Down 0.8%

Shares of NASDAQ NAGE opened at $5.06 on Friday. The stock has a market capitalization of $405.20 million, a PE ratio of 25.30 and a beta of 2.11. The stock’s fifty day simple moving average is $5.74 and its two-hundred day simple moving average is $7.12. Niagen Bioscience has a 12-month low of $4.72 and a 12-month high of $14.69.

Institutional Investors Weigh In On Niagen Bioscience

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in NAGE. New York State Teachers Retirement System acquired a new stake in Niagen Bioscience in the fourth quarter worth about $30,000. Financial Consulate Inc. purchased a new position in shares of Niagen Bioscience in the 3rd quarter valued at approximately $33,000. State of Alaska Department of Revenue purchased a new position in shares of Niagen Bioscience in the 3rd quarter valued at approximately $44,000. Ameritas Investment Partners Inc. acquired a new stake in Niagen Bioscience in the 3rd quarter worth approximately $45,000. Finally, North Star Investment Management Corp. acquired a new stake in Niagen Bioscience in the 3rd quarter worth approximately $47,000. 15.41% of the stock is currently owned by hedge funds and other institutional investors.

Key Niagen Bioscience News

Here are the key news stories impacting Niagen Bioscience this week:

• Positive Sentiment: Q4 beat and profit strength — Niagen reported quarterly EPS that topped estimates and stronger-than-expected revenue; media coverage notes the company doubled annual profit and management signaled an acquisition hunt and expansion into GLP‑1-style products, which drove significant after-hours buying interest. Niagen Bioscience Doubles Annual Profit (MSN)
• Positive Sentiment: Quarterly beat confirmed by multiple outlets — Coverage and transcripts highlight strong revenue growth and an EPS beat for Q4, supporting the narrative of improving operations and profitability. NAGE Tops Q4 Earnings (Zacks)
• Neutral Sentiment: Price target tweak but rating intact — Canaccord trimmed its price target from $14 to $13 while maintaining a “buy” rating, signaling continued analyst conviction but a more conservative valuation. Canaccord Price Target Update (Benzinga)
• Neutral Sentiment: HC Wainwright updated multi-quarter and FY2027 EPS models — the firm published a full set of quarterly and FY2027 estimates (FY2027 ~$0.37 EPS), providing a new baseline for investor expectations (mixed across quarters).
• Negative Sentiment: Revenue guidance below street estimates — Niagen issued FY2026 revenue guidance of $142.4M–$148.8M versus a consensus around $153.3M, which reduces near-term top-line visibility and likely pressured the share price despite the quarterly beat. Valuation After New 2026 Guidance (Yahoo)
• Negative Sentiment: Analyst cuts to FY2026 and near-term quarters — HC Wainwright reduced FY2026 EPS (from $0.38 to $0.33) and cut Q2 2026 materially, which may weigh on sentiment as models are reset lower despite stronger Q4 results.

About Niagen Bioscience

Niagen Bioscience, Inc is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company’s patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen. It operates through the following segments: Consumer Products, Ingredients, and Analytical Reference Standards and Services.